Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) and Foghorn Therapeutics (NASDAQ:FHTX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends and analyst recommendations.
Valuation and Earnings
This table compares Arcadia Biosciences and Foghorn Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Arcadia Biosciences | $5.17 million | 0.97 | -$7.04 million | $2.54 | 1.44 |
| Foghorn Therapeutics | $22.60 million | 10.93 | -$86.62 million | ($1.13) | -3.87 |
Profitability
This table compares Arcadia Biosciences and Foghorn Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Arcadia Biosciences | -97.97% | -8.80% | -5.15% |
| Foghorn Therapeutics | -294.16% | N/A | -29.62% |
Volatility and Risk
Arcadia Biosciences has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Comparatively, Foghorn Therapeutics has a beta of 3.04, suggesting that its stock price is 204% more volatile than the S&P 500.
Institutional & Insider Ownership
17.7% of Arcadia Biosciences shares are held by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are held by institutional investors. 8.2% of Arcadia Biosciences shares are held by insiders. Comparatively, 7.6% of Foghorn Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Arcadia Biosciences and Foghorn Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Arcadia Biosciences | 1 | 0 | 0 | 0 | 1.00 |
| Foghorn Therapeutics | 1 | 0 | 6 | 2 | 3.00 |
Foghorn Therapeutics has a consensus target price of $11.13, indicating a potential upside of 154.58%. Given Foghorn Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Foghorn Therapeutics is more favorable than Arcadia Biosciences.
Summary
Foghorn Therapeutics beats Arcadia Biosciences on 9 of the 15 factors compared between the two stocks.
About Arcadia Biosciences
Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.
About Foghorn Therapeutics
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
